Scancell Signs Antibody Licence Agreement with Cancer Research Technology

Published: Aug 10, 2010

NOTTINGHAM, England--(BUSINESS WIRE)--Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, and Cancer Research Technology Ltd (‘CRT’) - Cancer Research UK’s commercialisation and development arm - today announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7.

Back to news